Avidity of onconeural antibodies is of clinical relevance

Cancer Immunol Immunother. 2013 Aug;62(8):1393-6. doi: 10.1007/s00262-013-1442-6. Epub 2013 Jun 4.

Abstract

Onconeural antibodies are important in the detection of paraneoplastic neurological syndromes (PNS). The avidity of Hu, Yo, and CRMP5 antibodies from 100 patients was determined by immunoprecipitation (IP), and 13 of the Yo positive sera were also tested by surface plasmon resonance (SPR). There was a significant association between the results from IP and SPR. Yo antibodies had higher avidity than Hu and CRMP5 antibodies, and both high- and low-avidity antibodies were associated with tumors and PNS. High-avidity Yo antibodies were mainly associated with ovarian cancer, whereas high-avidity Hu and CRMP5 antibodies were mainly associated with small-cell lung cancer. Low-avidity CRMP5 and Yo antibodies were less often detected by a commercial line blot than high-avidity antibodies. The failure to detect low-avidity onconeural antibodies may result in under diagnosis of PNS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neoplasm / blood
  • Antibodies, Neoplasm / immunology*
  • Antibody Affinity*
  • ELAV Proteins / immunology
  • Humans
  • Hydrolases
  • Immunoprecipitation
  • Microtubule-Associated Proteins
  • Nerve Tissue Proteins / immunology
  • Paraneoplastic Syndromes / blood
  • Paraneoplastic Syndromes / diagnosis*
  • Paraneoplastic Syndromes / immunology*
  • Sensitivity and Specificity
  • Surface Plasmon Resonance

Substances

  • Antibodies, Neoplasm
  • CDR2 protein, human
  • ELAV Proteins
  • Microtubule-Associated Proteins
  • Nerve Tissue Proteins
  • DPYSL5 protein, human
  • Hydrolases